Tianjin pharma group known for Xuebijing, a TCM injection used in hospital intensive-care and sepsis treatment.
Tianjin pharma group known for Xuebijing, a TCM injection used in hospital intensive-care and sepsis treatment.
Sells Xuebijing, a Chinese-medicine injection given in hospital intensive care, to hospitals through distributors, so sales depend on staying on China's reimbursement lists and on how widely doctors use it. A retail pharmacy chain adds a second line selling other makers' medicines to consumers.
In one line: A Chinese hospital-injectable TCM maker.
Moat: narrow (brand, regulatory licence). Established hospital-injectable brand with wide ICU adoption and reimbursement listing.
Headquarters: Tianjin, China · Employees: 4,852
Size Tianjin Chase Sun Pharmaceutical (300026.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.23B, the 1818th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.00 on 18 Nov 2026.
Performance Over six months the shares fell 9.6%, against -22.2% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 29.0% over the last twelve months (peer median +7.6%); the operating margin is 2.8% (peer median -18.6%).
Valuation It trades at 21.3× forward earnings against a peer median of 22.1× (5th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (7.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.90B | CN¥4.90B | CN¥5.74B | CN¥6.07B | CN¥6.61B |
| Revenue growth | — | -15% | -5% | -8% | — |
| Gross profit | CN¥2.61B | CN¥2.65B | CN¥2.81B | CN¥3.07B | CN¥3.60B |
| EBITDA | n/a | CN¥523M | CN¥447M | CN¥862M | CN¥1.06B |
| Net income | CN¥25.8M | CN¥18.5M | CN¥21.5M | CN¥507M | CN¥624M |
| Free cash flow | CN¥659M | CN¥681M | CN¥654M | CN¥1.18B | -CN¥23.2M |
| Capital expenditure | CN¥110M | CN¥130M | CN¥193M | CN¥347M | CN¥770M |
| Total debt | CN¥374M | CN¥540M | CN¥897M | CN¥1.58B | CN¥2.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Tianjin Chase Sun Pharmaceutical 300026.SZ | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% |
| Tasly Pharmaceutical 600535.SS | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300026.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.1% | -6.2% | 9th highest of 21 |
| 6-month return | -9.6% | -22.2% | 8th highest of 21 |
| Distance from 52-week high | -24.8% | -42.2% | 4th highest of 21 |
| Revenue growth (TTM) | -29.0% | +7.6% | 2nd lowest of 18 |
| Operating margin | 2.8% | -18.6% | 6th highest of 18 |
| Forward P/E | 21.3× | 22.1× | 5th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 7.0% | 2.5% | 2nd most demanding of 6 |
| Growth delivered (Del g) | -5.3% | -1.3% | 3rd lowest of 6 |
| Hurdle (Req g minus delivered) | +12.3 pp | +1.0 pp | 2nd most demanding of 6 |
| ROIC minus cost of capital | -4.0 pp | -9.4 pp | 6th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |